Join to view full profile
3181 SW Sam Jackson Park RdPortland, OR 97239
Phone+1 503-314-7168
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Shivaani Kummar, MD is an oncologist in Portland, Oregon. She is currently licensed to practice medicine in Oregon, California, and California.
Education & Training
Lady Hardinge Medical CollegeClass of 1995
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology
Certifications & Licensure
CA State Medical License 2014 - 2028
OR State Medical License 2020 - 2027- CA State Medical License 2014 - 2026
MD State Medical License 1996 - 2018
CT State Medical License 2000 - 2004
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Publications & Presentations
PubMed
- 3 citationsNirogacestat-the pathway to approval of the first treatment for desmoid tumors, a rare disease.Shivaani Kummar, Nam Bui, Wells A Messersmith, Jeanne Whiting, Marlene Portnoy
Therapeutic Advances in Rare Disease. 2025-02-11 - 4 citationsFirst-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.Shivaani Kummar, Albiruni Abdul Razak, Scott Laurie, Dylan M Glatt, Sariah Kell
Cancer Research Communications. 2025-01-01 - 9 citationsImmunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, Alexandra Drakaki, Danny N Khalil
The Journal of Experimental Medicine. 2024-10-07
Press Mentions
The Knight Cancer Challenge’s Enduring Legacy: Celebrating a Decade of Cancer Research, Care, PreventionJune 24th, 2025- AACR Annual Meeting 2023: Phase III Immunotherapy Trials Offer Hope for Patients with Lung, Liver, and Biliary Tract CancersMay 4th, 2023
- The Topic of CancerJune 16th, 2022
Grant Support
- Experimental Therapeutics in Cancer Training ProgramOREGON HEALTH & SCIENCE UNIVERSITY2025–2029
- OHSU Knight Cancer InstituteOREGON HEALTH & SCIENCE UNIVERSITY1997–2027
- [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumorsOREGON HEALTH & SCIENCE UNIVERSITY2021–2026
